Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pandemic prevention

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Pandemic prevention. Displaying page 1 of 1.
    EudraCT Number: 2007-000115-28 Sponsor Protocol Number: 109817 Start Date*: 2007-07-16
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase II, open, non-randomized study designed to evaluate the reactogenicity and immunogenicity of one or two booster administrations of an influenza pandemic candidate vaccine (GSK1562902A) in a...
    Medical condition: Since 1997, avian H5N1 influenza has caused several human infections and high mortality rate in Southeast Asia. Experts warn that the next influenza pandemic is imminent and could be severe. Preven...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000165-38 Sponsor Protocol Number: V87P1E1 Start Date*: 2007-06-22
    Sponsor Name:NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.
    Full Title: A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of FLUAD-H5N1 (Surface Antigen Adjuvanted with MF59C.1) Influenza Vaccine in Non-elderly Adult an...
    Medical condition: Active immunoprofilaxis against potential pandemic influenza strain.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059429 Influenza immunisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-003244-27 Sponsor Protocol Number: PANORAMIC-Norway Start Date*: 2023-04-11
    Sponsor Name:Helse Bergen HF
    Full Title: PAxlovid loNg cOvid-19 pRevention triAl with recruitMent In the Community in Norwayy
    Medical condition: COVID-19 SARS-CoV-2
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004848 10084355 COVID-19 virus test positive LLT
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003592-35 Sponsor Protocol Number: LAIVImmuno Start Date*: 2014-04-07
    Sponsor Name:Public Health England
    Full Title: A phase III/IV open-label study of the immunogenicity and safety of a single dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for each of three successive years in children naïve to, o...
    Medical condition: Protection against influenza in healthy children
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10059430 Influenza immunization LLT
    14.1 10042613 - Surgical and medical procedures 10046859 Vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    14.1 10042613 - Surgical and medical procedures 10039244 Routine vaccination LLT
    14.1 10042613 - Surgical and medical procedures 10016794 Flu vaccination LLT
    Population Age: Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001565-37 Sponsor Protocol Number: PrEP_COVID Start Date*: 2020-04-03
    Sponsor Name:ISGlobal
    Full Title: PRE-EXPOSURE PROPHYLAXIS WITH HYDROXYCHLOROQUINE FOR HIGH-RISK HEALTHCARE WORKERS DURING THE COVID-19 PANDEMIC (PrEP_COVID): A UNICENTRIC, DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL.
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-014765-74 Sponsor Protocol Number: Fluval P-H-08 Start Date*: 2009-08-13
    Sponsor Name:Omninvest Ltd.
    Full Title: Tolerability and Safety Study of Fluval P Monovalent Influenza Vaccine in Children
    Medical condition: Immunization of children against infection caused by pandemic influenza (H1N1)09 virus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059429 Influenza immunisation LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-001514-97 Sponsor Protocol Number: 114541 Start Date*: 2015-05-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 3, observer blind, randomized, non-influenza vaccine comparator-controlled, multi-country and multi-centre study of the efficacy of GSK Biologicals’ quadrivalent, inactivated, split virion,...
    Medical condition: Healthy volunteers (Immunization against influenza in male and female subjects 3 to 8 years of age inclusive)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-013105-34 Sponsor Protocol Number: 810706 Start Date*: 2009-11-09
    Sponsor Name:Baxter Innovations GmbH
    Full Title: A PHASE I/II STUDY TO ASSESS THE SAFETY AND IMMUNOGENICITY OF A VERO CELL-DERIVED WHOLE VIRUS H5N1 INFLUENZA VACCINE IN HEALTHY INFANTS, CHILDREN AND ADOLESCENTS AGED 6 MONTHS TO 17 YEARS
    Medical condition: Prophylaxis of influenza infection caused by a pandemic influenza virus (H5N1)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10059430 Influenza immunization LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022817-24 Sponsor Protocol Number: OVG 2010/03 Start Date*: 2010-10-18
    Sponsor Name:University of Oxford
    Full Title: A multi-centre, open-label, clinical, phase 4 trial, following on from a head-to-head comparison study of two H1N1 influenza vaccines in children, to compare firstly, the persistence of antibody ag...
    Medical condition: Prevention of Influenza infections
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059429 Influenza immunisation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014807-30 Sponsor Protocol Number: Fluval P-H-07 Start Date*: 2009-08-13
    Sponsor Name:Omninvest Ltd.
    Full Title: Tolerability and Immunogenicity Study of Fluval P Monovalent Influenza Vaccine in Children and Adolescents
    Medical condition: Immunization of children and adolescents against infection caused by pandemic influenza (H1N1)09 virus.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10059429 Influenza immunisation LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2019-002939-28 Sponsor Protocol Number: OVX836-002 Start Date*: 2019-11-07
    Sponsor Name:OSIVAX
    Full Title: A phase 2a, single center, randomized, observer blind, controlled study to evaluate the immunogenicity and the safety of one dose of OVX836 influenza vaccine at two dose levels (90 µg and 180 μg), ...
    Medical condition: Healthy Volunteers (influenza Vaccine) Influenza infection is a major cause of respiratory disease that affects all age groups, leading to significant morbidity and mortality. Complications of infl...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-005732-29 Sponsor Protocol Number: MOM-M281-011 Start Date*: 2021-11-19
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generali...
    Medical condition: Myasthenia gravis (MG).
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001673-75 Sponsor Protocol Number: ABX464-401 Start Date*: 2020-05-06
    Sponsor Name:ABIVAX
    Full Title: A phase 2/3, randomized, double blind, placebo-controlled study to evaluate the efficacy and the safety of ABX464 in treating inflammation and preventing COVID-19 associated acute respiratory failu...
    Medical condition: COVID-19 infection (infection with SARS-CoV-2 virus)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) BE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014719-11 Sponsor Protocol Number: 2009/08 H1N1 Start Date*: 2009-09-18
    Sponsor Name:University of Oxford
    Full Title: Open Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Baxter H1N1 vaccine and GlaxoSmithKline H1N1 vaccine in children 6 months to 12...
    Medical condition: Prophylaxis of influenza in an officially declared pandemic situation.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059429 Influenza immunisation LLT
    12.0 10059637 Influenza antibody test LLT
    12.0 10059642 Influenza antibody test positive LLT
    12.0 10059643 Influenza antibody test negative LLT
    12.0 10060063 Influenza serology LLT
    12.0 10060078 Influenza serology positive LLT
    12.0 10060079 Influenza serology negative LLT
    12.0 10022000 Influenza LLT
    12.0 10022002 Influenza A virus infection LLT
    12.0 10022001 Influenza (epidemic) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-003786-41 Sponsor Protocol Number: V70P5 Start Date*: 2007-10-22
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vacci...
    Medical condition: no medical, condition: healthy,
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Completed) IT (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000558-11 Sponsor Protocol Number: 810705 Start Date*: 2008-06-26
    Sponsor Name:Baxter Innovations GmbH
    Full Title: An Open-Label Phase III Study to Assess the Safety and Immunogenicity of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in an Adult and Elderly Population as well as in Specified Risk Groups
    Medical condition: H5N1 vaccination in healthy subjects (adult and elderly population) and in specified risk groups (chronically ill, transplant and HIV patients).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) LV (Completed) FI (Completed) LT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 16:17:37 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA